CDK7是一种新的治疗点,用于纤维状瘤的治疗
Manabu Nukaya1, Patrick R Carney1, Crystal Cafferty1
1Department of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
iScience
|December 1, 2025
概括
向循环素依赖性激酶7 (CDK7) 显示出治疗罕见纤维状瘤 (FLC) 的前景. 抑制CDK7可以杀死FLC癌细胞并改善治疗反应,为患者提供新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 纤维状瘤 (FLC) 是一种罕见的,攻击性的肝癌,主要影响年轻人.
- 目前用于不可切割的FLC的治疗方法提供了有限的生存益处,五年生存率在30-45%之间.
- 在FLC中,对于新的治疗策略和药物点有着至关重要的未满足的需求.
研究的目的:
- 调查循环林依赖性激酶7 (CDK7) 在FLC病变发生中的作用.
- 在FLC模型中评估CDK7抑制的治疗潜力.
- 探索涉及CDK7抑制剂的组合疗法,以加强FLC治疗.
主要方法:
- 对患者获得的FLC样本进行分析,以确定关键的分子通路.
- 使用患者衍生FLC模型来测试CDK7抑制剂的疗效.
- 剂量反应研究,以评估在 CDK7 抑制后的癌细胞死亡.
- 研究CDK7抑制剂与其他候选药物的协同作用.
主要成果:
- 异常的CDK7功能被确定为FLC细胞身份和生存的关键.
- 抑制CDK7有效地抑制了FLC必不可少的致癌途径.
- 药理上抑制CDK7导致了体外和患者衍生模型中的剂量依赖的FLC癌细胞死亡.
- 与其他药物联合抑制CDK7的疗效增加.
结论:
- CDK7是FLC的关键驱动因素,是一个有前途的治疗标.
- 向CDK7为纤维状瘤患者提供了潜在的新治疗策略.
- 涉及CDK7抑制剂的组合疗法可能会改善FLC的治疗结果.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


